FERRING PHARMACEUTICALS A/S: Financial statements 2023
CVR: 16313440
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
FERRING PHARMACEUTICALS A/S (CVR 16313440) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 1,457,509,000 and a net result of DKK 67,110,000 compared with DKK 52,377,000 the year before. That is an increase of 15.5% compared with the year before. The profit margin was 4.6%. Equity in the 2023 report amounted to DKK 189,325,000. The solvency ratio was 32.3%. The company had 497 employees in the financial year.
- Revenue
- DKK 1,457,509,000
- Gross Profit
- DKK 707,843,000
- Profit/Loss
- DKK 67,110,000
- Equity
- DKK 189,325,000
- Total Assets
- DKK 586,405,000
- Employees
- 497
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 1.5B | 707.8M | 67.1M | 189.3M | 497 |
| 2022 | 1.3B | 645.9M | 52.4M | 122M | 559 |
| 2021 | 1B | 1B | 40.2M | 69.6M | 487 |
| 2020 | 1.1B | 1.1B | 40.9M | 79.4M | 497 |
| 2019 | 1.4B | 1.4B | 38.3M | 106.5M | 533 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of December 22, 2023, Klaus Grønbæk Jakobsen is registered as director of FERRING PHARMACEUTICALS A/S.
As of December 22, 2023, Lene Melchiorsen is registered as director of FERRING PHARMACEUTICALS A/S.
As of August 11, 2023, Armin Metzger has joined the board of directors of FERRING PHARMACEUTICALS A/S.
As of August 1, 2023, Bolette Wildt has stepped down as director of FERRING PHARMACEUTICALS A/S.
FERRING PHARMACEUTICALS A/S has published its annual report for 2022. Revenue came to DKK 1,261,432,000, and the net result was DKK 52,377,000.
About FERRING PHARMACEUTICALS A/S
FERRING PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 1992. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named FERRING NORDIC PHARMACEUTICALS A/S and A/S PSE 38 NR. 1587. The management consists of Jan Peutzfeldt, Ingbritt Tolstrup Birk and Jesper Thomsen. The board consists of Marianne Kock (chair), Dag Frederik Arfst Paulsen and Jean-Frederic Paulsen. The company is owned by Ferring B.V.. The company has 522 employees (2026). In 2025, the company reported revenue of DKK 1,730,413,000 and a net result of DKK 49,005,000 compared with DKK 76,890,000 the year before. Equity in the 2025 report amounted to DKK 315,220,000.